Developer docs
API playgroundTry for free, no card

Search company profiles

Shape Therapeutics

Full company profile

uuid0000419

Namestring
Shape Therapeutics
Legal namestring
Shape Therapeutics Inc.
Websiteurl
shapetx.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Shape Therapeutics (operating as ShapeTX) is a Seattle-based biotechnology company founded in 2018 that develops programmable RNA medicines by combining RNA biology, AAV delivery, and generative AI within a single integrated platform. The company markets four core technology modules: RNAfix®, which recruits endogenous ADAR enzymes to edit RNA without altering DNA; AAVid™, an AI-driven capsid engineering platform that screens billions of viral capsid variants for tissue-specific delivery; TruStable™, a stable cell line system for scalable AAV manufacturing; and RNAswap™, a broader RNA manipulation technology. These sit on top of a proprietary AI engine that uses diffusion-based generative models and massive parallel screening datasets to design guide RNAs and capsids with high on-target efficiency and specificity.

The company is pre-commercial and monetizes through strategic licensing and collaboration agreements with pharmaceutical partners rather than direct product sales. Named enterprise customers include Roche (2021 collaboration expanded 2023, reportedly acquired ShapeTX in 2024 for ~$3B per third-party sources), Otsuka (September 2023 ocular disease collaboration), and VectorY Therapeutics (September 2025 AAV5 capsid option and license agreement worth up to $1.2B). ShapeTX also pursues a wholly-owned pipeline, with a Parkinson's disease AAV gene therapy program highlighted at the ESGCT 2025 congress, and reports preclinical proof-of-platform data including >90% RNA editing efficiency in non-human primate brain. Backed by approximately $147.5M in disclosed venture funding (Series A 2019 and $112M Series B in 2021), ShapeTX operates in the 101–250 employee range and is led by co-founder and CEO Francois Vigneault, PhD, alongside a scientific advisory board that includes George Church (Harvard), Don Cleveland (UCSD), and James Collins (MIT).

Short descriptiontext

Shape Therapeutics is a Seattle-based biotech developing AI-powered programmable RNA medicines, combining RNA editing (RNAfix®), AI-engineered AAV delivery (AAVid™), and scalable manufacturing (TruStable™) to serve pharmaceutical partners through licensing and collaboration agreements.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeattle, United States
HQ citystring
Seattle
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
RNA editing technology, gene therapy platforms, AAV delivery systems, programmable RNA medicine, AI-powered drug discovery
Industry3 codes
PRIMARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAADAF
RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Gene Therapy & RNA-based Therapeutics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing and Collaboration Agreements
TypeLicensing Royalties
Description

Shape Therapeutics generates revenue through strategic licensing agreements and collaborations with pharmaceutical companies. This includes the Roche collaboration (August 2021, expanded November 2023) for neuroscience and rare disease applications, Otsuka collaboration (September 2023) for ocular diseases, and VectorY licensing agreement (September 2025) potentially worth up to $1.2 billion. Revenue comes from upfront payments, milestone payments, and potential royalties on commercialized products.

shapetx.com
2Future Product Commercialization
TypeOne Time License
Description

The company is developing its own pipeline of gene therapy candidates including treatments for Parkinson's disease and other CNS disorders. Once clinical candidates advance through development, the company could commercialize products directly.

futuremarketinsights.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 4 records shown
1RNAfix®
Description

RNA editing platform that recruits ADAR enzyme to correct RNA mutations without changing DNA

shapetx.com
+3 more records
Core offering1 text field

Shape Therapeutics develops AI-powered programmable RNA medicines and gene therapy platforms. Its core offering combines RNA editing technology (RNAfix®), AI-driven AAV capsid engineering (AAVid™), and scalable manufacturing (TruStable™) to enable discovery, design, delivery, and production of RNA-based therapeutics targeting genetic diseases, particularly CNS disorders. The company monetizes through licensing deals with pharmaceutical partners and is advancing an internal pipeline including Parkinson's disease gene therapy candidates.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • >90% editing efficiency achieved in mouse and non-human primate brain tissue with RNAfix® platform
+2 more records
Product overview1 text field

Shape Therapeutics (ShapeTX) is a biotechnology company developing a unified programmable RNA medicine platform. The platform integrates multiple proprietary technologies: RNAfix® for RNA editing, AAVid™ for AI-driven AAV capsid engineering, TruStable™ for stable cell line manufacturing, RNAswap™ for additional RNA applications, and a core AI Engine that powers the entire discovery process. These technologies work together to enable end-to-end gene therapy development - from target identification through AI-powered RNA design to precise delivery via engineered AAV capsids to scalable manufacturing using stable cell lines.

Product and service6 records
1RNAfix®
CategoryRNA Editing Technology Platform
Description

RNA editing platform that recruits ADAR (adenosine deaminase acting on RNA), a naturally occurring enzyme found in all human cells, to correct the body's instructions for making proteins by recoding RNA without permanent changes to DNA. Can be applied to correct mutations or purposefully create them to treat genetic disorders. Licensed to pharmaceutical partners for therapeutic development.

2AAVid™
CategoryAAV Delivery Technology Platform
Description

AI-driven AAV capsid engineering platform that rationally designs and screens billions of viral capsid variants to identify those that can precisely deliver RNA medicines to specific tissues or cells while avoiding off-target effects. Licensed to pharma and biotech partners for targeted gene therapy delivery.

3TruStable™
CategoryBiomanufacturing Platform
Description

Stable cell line manufacturing technology that dramatically improves the ability to manufacture RNA medicines and AAV vectors at any scale, from dozens to millions of doses. Enables scalable production of gene therapy products.

4RNAswap™
CategoryRNA Technology Platform
Description

RNA technology platform for therapeutic RNA manipulation, complementing the RNAfix editing platform with additional RNA-based therapeutic applications.

5ShapeTX AI Engine
CategoryAI Drug Discovery Engine
Description

Proprietary AI platform that analyzes massive datasets generated across ShapeTX's entire technology suite and therapeutic portfolio for intelligent decision making in drug discovery. Combines breakthroughs in AI, RNA technology, and synthetic biology to design novel therapeutic candidates.

6Payloads Platform
CategoryAI-powered RNA Payload Design Platform
Description

AI-powered platform for designing novel RNAs that reprogram cells to prevent or fight disease, from correcting mutations to fine-tuning gene expression to modulating protein-protein interactions. Screens massive genomic datasets to find treatment possibilities for difficult-to-treat diseases.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1VectorY Therapeutics
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-18
Description

VectorY Therapeutics and ShapeTX announced option and license agreement to advance vectorized antibodies for neurodegenerative diseases using an AAV5-derived CNS capsid. Deal potentially worth up to $1.2 billion including upfront, option exercise, and milestone payments plus royalties.

biospace.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-09-07
Description

Otsuka collaborates with ShapeTX to develop novel AAV gene therapies for ocular diseases using ShapeTX's AAV capsid and delivery technology platforms.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-08-24
Description

ShapeTX entered strategic research collaboration with Roche to advance AAV-based RNA editing technology for neuroscience and rare disease indications. The collaboration was expanded in November 2023 with addition of a new target. Roche acquired Shape Therapeutics in 2024 for approximately $3 billion.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

ShapeTX participates in the CGT Science Series, a quarterly webinar collaboration between ASGCT, BIO, and CBER (FDA) that facilitates technical exchange between sponsors and regulators on cell and gene therapy topics including CMC guidance and gene editing technologies.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage RNA editing company also leveraging ADAR-mediated RNA editing. Most direct competitor to ShapeTX's RNAfix® platform, with overlapping therapeutic focus on genetic diseases.

TypeDirect peer
Description

RNA therapeutics company developing stereopure oligonucleotide and RNA editing candidates for CNS and rare diseases. Competes with ShapeTX across both RNA editing modality and CNS delivery focus.

TypeDirect peer
Description

RNA editing / oligonucleotide therapeutics company developing Axiomer® ADAR-mediated RNA editing platform. Directly comparable to RNAfix® in modality and disease-area focus.

TypeBroad incumbent
Description

Clinical-stage base editing company with broader genetic medicine portfolio. Competes with ShapeTX in next-generation nucleic-acid editing modalities and has substantially more capital and clinical-stage assets.

TypeBroad incumbent
Description

Gene editing company developing prime editing technology. Operates in adjacent editing modality space and competes for partner interest and capital in the programmable medicine category.

TypeBroad incumbent
Description

Clinical-stage CRISPR/Cas9 gene editing company with in vivo and ex vivo programs. Larger, more advanced competitor that overlaps with ShapeTX's vision of programmable gene medicines.

TypeBroad incumbent
Description

Clinical-stage CRISPR gene editing company. Comparable as an established player in the gene editing space targeting similar genetic disease indications, though using a different editing modality.

TypeDirect peer
Description

Clinical-stage AAV gene therapy company using directed-evolution AAV capsid engineering. Direct competitor to ShapeTX's AAVid™ platform with overlapping therapeutic indication areas including CNS and ophthalmology.

TypeDirect peer
Description

AI-driven AAV capsid engineering company with partnerships across multiple pharma companies. Comparable technology focus to ShapeTX's AAVid™ and competes for similar partner relationships.

TypeBroad incumbent
Description

Established commercial-stage RNA therapeutics leader. While operating in siRNA rather than RNA editing, Alnylam is the dominant public benchmark for the RNA therapeutics category and represents the long-term commercial archetype.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles19 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Shape Therapeutics

Gene Therapy & RNA-based Therapeuticsshapetx.com

Shape Therapeutics is a Seattle-based biotech developing AI-powered programmable RNA medicines, combining RNA editing (RNAfix®), AI-engineered AAV delivery (AAVid™), and scalable manufacturing (TruStable™) to serve pharmaceutical partners through licensing and collaboration agreements.

What Shape Therapeutics does

Shape Therapeutics (operating as ShapeTX) is a Seattle-based biotechnology company founded in 2018 that develops programmable RNA medicines by combining RNA biology, AAV delivery, and generative AI within a single integrated platform. The company markets four core technology modules: RNAfix®, which recruits endogenous ADAR enzymes to edit RNA without altering DNA; AAVid™, an AI-driven capsid engineering platform that screens billions of viral capsid variants for tissue-specific delivery; TruStable™, a stable cell line system for scalable AAV manufacturing; and RNAswap™, a broader RNA manipulation technology. These sit on top of a proprietary AI engine that uses diffusion-based generative models and massive parallel screening datasets to design guide RNAs and capsids with high on-target efficiency and specificity.

The company is pre-commercial and monetizes through strategic licensing and collaboration agreements with pharmaceutical partners rather than direct product sales. Named enterprise customers include Roche (2021 collaboration expanded 2023, reportedly acquired ShapeTX in 2024 for ~$3B per third-party sources), Otsuka (September 2023 ocular disease collaboration), and VectorY Therapeutics (September 2025 AAV5 capsid option and license agreement worth up to $1.2B). ShapeTX also pursues a wholly-owned pipeline, with a Parkinson's disease AAV gene therapy program highlighted at the ESGCT 2025 congress, and reports preclinical proof-of-platform data including >90% RNA editing efficiency in non-human primate brain. Backed by approximately $147.5M in disclosed venture funding (Series A 2019 and $112M Series B in 2021), ShapeTX operates in the 101–250 employee range and is led by co-founder and CEO Francois Vigneault, PhD, alongside a scientific advisory board that includes George Church (Harvard), Don Cleveland (UCSD), and James Collins (MIT).

Shape Therapeutics firmographics

Firmographics
Name
Shape Therapeutics
Legal name
Shape Therapeutics Inc.
Website
https://shapetx.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
Shape Therapeutics is a Seattle-based biotech developing AI-powered programmable RNA medicines, combining RNA editing (RNAfix®), AI-engineered AAV delivery (AAVid™), and scalable manufacturing (TruStable™) to serve pharmaceutical partners through licensing and collaboration agreements.
Ownership category
akta.pro rank

Shape Therapeutics industry classification

Industry
Product category
Gene Therapy & RNA-based Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAADAF
RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

Keywords

  • RNA editing technology
  • Gene therapy platforms
  • AAV delivery systems
  • Programmable RNA medicine
  • AI-powered drug discovery

Where Shape Therapeutics is headquartered

Location

Headquarters

HQ city
Seattle
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Shape Therapeutics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Licensing and Collaboration Agreements: Shape Therapeutics generates revenue through strategic licensing agreements and collaborations with pharmaceutical companies. This includes the Roche collaboration (August 2021, expanded November 2023) for neuroscience and rare disease applications, Otsuka collaboration (September 2023) for ocular diseases, and VectorY licensing agreement (September 2025) potentially worth up to $1.2 billion. Revenue comes from upfront payments, milestone payments, and potential royalties on commercialized products.
  2. Future Product Commercialization: The company is developing its own pipeline of gene therapy candidates including treatments for Parkinson's disease and other CNS disorders. Once clinical candidates advance through development, the company could commercialize products directly.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Shape Therapeutics product offering

Product offering

Core offering

Shape Therapeutics develops AI-powered programmable RNA medicines and gene therapy platforms. Its core offering combines RNA editing technology (RNAfix®), AI-driven AAV capsid engineering (AAVid™), and scalable manufacturing (TruStable™) to enable discovery, design, delivery, and production of RNA-based therapeutics targeting genetic diseases, particularly CNS disorders. The company monetizes through licensing deals with pharmaceutical partners and is advancing an internal pipeline including Parkinson's disease gene therapy candidates.

Product overview

Shape Therapeutics (ShapeTX) is a biotechnology company developing a unified programmable RNA medicine platform. The platform integrates multiple proprietary technologies: RNAfix® for RNA editing, AAVid™ for AI-driven AAV capsid engineering, TruStable™ for stable cell line manufacturing, RNAswap™ for additional RNA applications, and a core AI Engine that powers the entire discovery process. These technologies work together to enable end-to-end gene therapy development - from target identification through AI-powered RNA design to precise delivery via engineered AAV capsids to scalable manufacturing using stable cell lines.

Differentiator

Problem solved

Functional benefit

Brands

  • RNAfix®: RNA editing platform that recruits ADAR enzyme to correct RNA mutations without changing DNA
  • RNAswap™
  • AAVid™
  • TruStable™

Products and services

  • RNAfix® RNA editing platform that recruits ADAR (adenosine deaminase acting on RNA), a naturally occurring enzyme found in all human cells, to correct the body's instructions for making proteins by recoding RNA without permanent changes to DNA. Can be applied to correct mutations or purposefully create them to treat genetic disorders. Licensed to pharmaceutical partners for therapeutic development.
  • AAVid™ AI-driven AAV capsid engineering platform that rationally designs and screens billions of viral capsid variants to identify those that can precisely deliver RNA medicines to specific tissues or cells while avoiding off-target effects. Licensed to pharma and biotech partners for targeted gene therapy delivery.
  • TruStable™ Stable cell line manufacturing technology that dramatically improves the ability to manufacture RNA medicines and AAV vectors at any scale, from dozens to millions of doses. Enables scalable production of gene therapy products.
  • RNAswap™ RNA technology platform for therapeutic RNA manipulation, complementing the RNAfix editing platform with additional RNA-based therapeutic applications.
  • ShapeTX AI Engine Proprietary AI platform that analyzes massive datasets generated across ShapeTX's entire technology suite and therapeutic portfolio for intelligent decision making in drug discovery. Combines breakthroughs in AI, RNA technology, and synthetic biology to design novel therapeutic candidates.
  • Payloads Platform AI-powered platform for designing novel RNAs that reprogram cells to prevent or fight disease, from correcting mutations to fine-tuning gene expression to modulating protein-protein interactions. Screens massive genomic datasets to find treatment possibilities for difficult-to-treat diseases.

Quantifiable outcome

  • >90% editing efficiency achieved in mouse and non-human primate brain tissue with RNAfix® platform
  • +2 more outcomes

Companies that use Shape Therapeutics

Customer profile

Named customers3 records

Segments2 records

Ideal customer profiles1 record

Shape Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature6 records

Shape Therapeutics partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • VectorY TherapeuticscoreStrategic or Co-development Partner · 18 September 2025VectorY Therapeutics and ShapeTX announced option and license agreement to advance vectorized antibodies for neurodegenerative diseases using an AAV5-derived CNS capsid. Deal potentially worth up to $1.2 billion including upfront, option exercise, and milestone payments plus royalties.
  • OtsukacoreStrategic or Co-development Partner · 7 September 2023Otsuka collaborates with ShapeTX to develop novel AAV gene therapies for ocular diseases using ShapeTX's AAV capsid and delivery technology platforms.
  • RochecoreStrategic or Co-development Partner · 24 August 2021ShapeTX entered strategic research collaboration with Roche to advance AAV-based RNA editing technology for neuroscience and rare disease indications. The collaboration was expanded in November 2023 with addition of a new target. Roche acquired Shape Therapeutics in 2024 for approximately $3 billion.
  • ASGCT / BIO / CBER (FDA)minorStrategic or Co-development PartnerShapeTX participates in the CGT Science Series, a quarterly webinar collaboration between ASGCT, BIO, and CBER (FDA) that facilitates technical exchange between sponsors and regulators on cell and gene therapy topics including CMC guidance and gene editing technologies.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Shape Therapeutics competitors and assessment

Company assessment

Direct peers

  • Korro Bio: Clinical-stage RNA editing company also leveraging ADAR-mediated RNA editing. Most direct competitor to ShapeTX's RNAfix® platform, with overlapping therapeutic focus on genetic diseases.
  • Wave Life Sciences: RNA therapeutics company developing stereopure oligonucleotide and RNA editing candidates for CNS and rare diseases. Competes with ShapeTX across both RNA editing modality and CNS delivery focus.
  • ProQR Therapeutics: RNA editing / oligonucleotide therapeutics company developing Axiomer® ADAR-mediated RNA editing platform. Directly comparable to RNAfix® in modality and disease-area focus.
  • 4D Molecular Therapeutics: Clinical-stage AAV gene therapy company using directed-evolution AAV capsid engineering. Direct competitor to ShapeTX's AAVid™ platform with overlapping therapeutic indication areas including CNS and ophthalmology.
  • Dyno Therapeutics: AI-driven AAV capsid engineering company with partnerships across multiple pharma companies. Comparable technology focus to ShapeTX's AAVid™ and competes for similar partner relationships.

Broad incumbents

  • Beam Therapeutics: Clinical-stage base editing company with broader genetic medicine portfolio. Competes with ShapeTX in next-generation nucleic-acid editing modalities and has substantially more capital and clinical-stage assets.
  • Prime Medicine: Gene editing company developing prime editing technology. Operates in adjacent editing modality space and competes for partner interest and capital in the programmable medicine category.
  • Intellia Therapeutics: Clinical-stage CRISPR/Cas9 gene editing company with in vivo and ex vivo programs. Larger, more advanced competitor that overlaps with ShapeTX's vision of programmable gene medicines.
  • Editas Medicine: Clinical-stage CRISPR gene editing company. Comparable as an established player in the gene editing space targeting similar genetic disease indications, though using a different editing modality.
  • Alnylam Pharmaceuticals: Established commercial-stage RNA therapeutics leader. While operating in siRNA rather than RNA editing, Alnylam is the dominant public benchmark for the RNA therapeutics category and represents the long-term commercial archetype.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Shape Therapeutics social profiles

Digital presence

Shape Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Shape Therapeutics leadership team

Management profile

Number of profiles

Profiles19 records

Shape Therapeutics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Shape Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Shape Therapeutics

What does Shape Therapeutics do?

Shape Therapeutics develops AI-powered programmable RNA medicines and gene therapy platforms. Its core offering combines RNA editing technology (RNAfix®), AI-driven AAV capsid engineering (AAVid™), and scalable manufacturing (TruStable™) to enable discovery, design, delivery, and production of RNA-based therapeutics targeting genetic diseases, particularly CNS disorders. The company monetizes through licensing deals with pharmaceutical partners and is advancing an internal pipeline including Parkinson's disease gene therapy candidates.

Is Shape Therapeutics a public or private company?

Shape Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Shape Therapeutics founded?

Shape Therapeutics was founded in 2018. It employs 11 to 50 people.

Where is Shape Therapeutics based?

Shape Therapeutics is headquartered in Seattle, United States, in the North America region.

How does Shape Therapeutics make money?

Two revenue lines are on record. Licensing and Collaboration Agreements are the primary driver. The others are future Product Commercialization.

Who are Shape Therapeutics's main competitors?

Direct peers on record are Korro Bio, Wave Life Sciences, ProQR Therapeutics, 4D Molecular Therapeutics and Dyno Therapeutics. Broad incumbents are Beam Therapeutics, Prime Medicine, Intellia Therapeutics, Editas Medicine and Alnylam Pharmaceuticals.

Does Shape Therapeutics have an API?

No public API is recorded for Shape Therapeutics.

What industry is Shape Therapeutics in?

Shape Therapeutics's product category is Gene Therapy & RNA-based Therapeutics. Its primary akta.pro industry code is HLAAADAG, RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics), with a secondary code of HLAAACAA, AAV Vector Gene Therapy Developers. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
LinkedInShape Therapeutics Inc.Shape Therapeutics will host two oral and two poster presentations at the American Society of Gene & Cell Therapy conference. The company aims to share data on its programmable RNA medicines, including AAV.ai delivery, RNA editing, and TruStable manufacturing platform.GlobeNewswireShape Therapeutics and Rett Syndrome Research Trust Announce Partnership to Advance a One-Time AI-Designed RNA Editing Therapy for Rett SyndromeShape Therapeutics and the Rett Syndrome Research Trust announced a partnership to advance SHP-401, an RNA editing therapy for Rett syndrome. The therapy targets the MECP2 R168X mutation, with preclinical data showing 70% editing and median lifespan extension from 50 to 174 days in mice. The collaboration will evaluate the therapy in non-human primates.ParkinsonsnewstodayNew MJFF grant to fund lab studies of Parkinson's gene therapyThe Michael J. Fox Foundation for Parkinson’s Research (MJFF) is providing funding to Shape Therapeutics to support lab studies of its experimental gene therapy SHP-201 for Parkinson’s disease. This grant will facilitate preclinical studies to gather data that may lead to an investigational new drug submission to U.S. regulators for clinical trials. The research aims to overcome significant challenges in delivering effective therapies targeting alpha-synuclein, a protein implicated in Parkinson’s pathology.FinancialContent Business PageShape Therapeutics Receives Research Grant from The Michael J. Fox Foundation for Parkinson’s Research to Advance SHP-201, a One-Time Gene Therapy to Treat Parkinson’s DiseaseShape Therapeutics has been awarded a research grant from The Michael J. Fox Foundation for Parkinson's Research to advance IND-enabling studies of SHP-201, the company's lead RNA-editing gene therapy candidate for Parkinson's disease. The grant will fund preclinical pharmacology, pharmacokinetic, biodistribution, and toxicology studies to support a planned Investigational New Drug submission for clinical trials. SHP-201 uses an engineered AAV capsid that crosses the blood-brain barrier to deliver an RNA-editing payload targeting the SNCA gene, aiming to reduce alpha-synuclein protein production, which is a key driver of neurodegeneration in Parkinson's disease.BioWorldMJFF grant supports Shape’s SHP-201 through IND-enabling studiesShape Therapeutics Inc. received a research grant from The Michael J. Fox Foundation for Parkinson's Research to advance SHP-201, its lead gene therapy candidate. The grant supports IND-enabling studies for the drug.BioSpaceShape Therapeutics Receives Research Grant from The Michael J. Fox Foundation for Parkinson’s Research to Advance SHP-201, a One-Time Gene Therapy to Treat Parkinson’s DiseaseShape Therapeutics received a research grant from The Michael J. Fox Foundation to advance IND-enabling studies of SHP-201, a one-time intravenous gene therapy targeting alpha-synuclein in Parkinson's disease. The grant will support preclinical pharmacology, pharmacokinetics, and safety studies to enable a clinical trial submission.GlobeNewswireShape Therapeutics Receives Research Grant from The Michael J. Fox Foundation for Parkinson’s Research to Advance SHP-201, a One-Time Gene Therapy to Treat Parkinson’s DiseaseShape Therapeutics received a research grant from The Michael J. Fox Foundation to advance IND-enabling studies of SHP-201, a one-time gene therapy for Parkinson's disease. The grant will support preclinical pharmacology, pharmacokinetics, and safety studies to enable a clinical trial submission. The therapy targets alpha-synuclein reduction via RNA editing.The Manila TimesShape Therapeutics Shares Breakthrough Preclinical Data for Non-Invasive Treatment of Parkinson’s Disease Using a Brain Targeted AAV Gene Therapy at the European Society of Gene & Cell Therapy 32nd AnShape Therapeutics presented preclinical data at ESGCT 32nd congress showing its Parkinson's disease gene therapy SHP-201 reduces alpha-synuclein in non-human primates. The engineered AAV5 capsid SHP-DB1 achieves 96% neuronal transduction in the substantia nigra. The company highlighted the therapy's potential as a first-in-class disease-modifying treatment.Drug Development and DeliveryShape Therapeutics Shares Breakthrough Preclinical Data for Non-Invasive Treatment of Parkinson’s Disease Using a Brain Targeted AAV Gene TherapyShape Therapeutics presented preclinical data at the ESGCT congress demonstrating that its gene therapy candidate SHP-201 effectively reduces alpha-synuclein in key brain regions of non-human primates. The therapy utilizes a novel BBB-penetrant AAV5 capsid, SHP-DB1, which achieved high neuronal transduction rates in the substantia nigra. These findings highlight the potential of this one-and-done gene editing approach to treat Parkinson's Disease.GlobeNewswireShape Therapeutics Shares Breakthrough Preclinical Data for Non-Invasive Treatment of Parkinson’s Disease Using a Brain Targeted AAV Gene Therapy at the European Society of Gene & Cell Therapy 32nd AnShape Therapeutics presented preclinical data for its Parkinson's disease gene therapy SHP-201 and its BBB-penetrant AAV5 capsid SHP-DB1 at ESGCT 32nd congress. The data showed SHP-DB1 achieved 96% neuronal transduction in the substantia nigra, and SHP-201 reduced functional SNCA by over 70% in non-human primates.